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Abstract
The study investigated the efficacy and safety of a combination therapy of 1,000mg aspirin (ASA) and 60mg
pseudoephedrine (PSE) on the symptoms of pain (combined score for headache and sore throat) and nasal congestion in
833 patients with acute upper respiratory tract viral infection (URTI), over 4 hours after a single dose in the clinic and over
3 days with multiple doses at home. The study demonstrated that over 4 hours in the clinic the combination ASA plus PSE
was superior to PSE or placebo for relief of pain symptomsmeasured subjectivelywith pain scores, andwas superior toASA
or placebo for relief of nasal congestion as measured objectively with rhinomanometry and subjectively with congestion
scores. After 3 days of treatment, ASA plus PSE was superior to PSE but not to placebo or ASA for global pain assessments,
and ASA plus PSE was superior to ASA and placebo but not to PSE for congestion assessments. No unexpected adverse
events occurred and no serious adverse events were attributed to study medicines. This study demonstrates that a
combination therapy of ASA plus PSE provides safe and effective relief of both common cold pain related symptoms and nasal
congestion. [Correction added on March 7, 2014 after first online publication: “Version: 4.0” was deleted from the title.]
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Acute upper respiratory tract viral infections (URTI) are
one of the most common human diseases with adults
suffering 2–5 symptomatic infections a year and most
school children having 7–10 URTI.1 Even with the most
conservative estimate of two URTI a year per person this
would indicate at least 600 million cases of URTI (colds
and flu) each year in the USA. Over 200 serologically
different viral types from eight different groups of viruses
are responsible for human URTI’s with the rhinoviruses
being themost common cause.1,2 The symptoms of URTI’s
are so common that self-diagnosis is normal amongst the
general public3 and symptomatic self-treatments with non-
prescription medicines are the most common therapy.
Symptoms of URTI are caused by the immune
response to viral infection,4 which generates a complex
mix of pro-inflammatory mediators with bradykinin
prostaglandins and numerous cytokines causing vasodi-
lation of blood vessels, glandular secretion, pain, and
fever.3 Vasodilation of nasal blood vessels causes the
symptom of nasal congestion by swelling venous sinuses
in the nasal epithelium and this causes nasal obstruc-
tion.3,5 The inflammatory mediators bradykinin and
prostaglandins cause pain related symptoms such as
sore throat, headache, sinus pain, muscle aches, and ear
ache.3 Nasal congestion can be treated by sympathomi-
metics such as pseudoephedrine that cause a constriction
of the nasal venous sinuses.5,6 The nasal blood vessels are
the most sensitive blood vessels in the body to circulating
sympathomimetics being five times more sensitive than
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the heart7 and this allows sympathomimetics such as
pseudoephedrine to cause nasal decongestion without any
significant cardiovascular side effects. Pain related
symptoms can be treated by analgesics such as aspirin
that inhibit prostaglandin synthesis.8,9 The syndrome of
symptoms occurringwithURTI involves the simultaneous
occurrence of several symptoms and nasal congestion and
pain related symptoms commonly occur together.9–11
This study investigates the safety and efficacy of a
symptomatic treatment for nasal congestion and pain
symptoms associated with URTI, containing a fixed
combination of both aspirin and pseudoephedrine. The
rationale for the combination treatment is that both
symptoms of congestion and pain commonly occur
simultaneously and that a combination treatment provides
a simplification of therapy compared to use of aspirin and
pseudoephedrine as mono-therapies.
Methods
Patients
The study was performed on patients with nasal
congestion and pain associated with URTI of no more
than 3 days duration. The study was conducted at a single
study center, at the Common Cold Centre, Cardiff
University, UK. Patients were required to have an overall
pain symptom (composite score for sore throat and/or
headache) of at least moderate intensity, as recorded on a
4-point categorical scale consisting of no pain¼ 0, mild
pain¼ 1, moderate pain¼ 2, and severe pain¼ 3, and at
the same time nasal obstruction with a total nasal air flow
resistance (NAR) of >0.25 Pa/cm3 second as determined
by posterior rhinomanometry.12 Patients with a nasal
resistance within the normal range at screening were
excluded (0.25 Pa/cm3).13 The main reasons for exclu-
sion were, allergic rhinitis, chronic respiratory disease,
hyperthyroidism, cardiovascular disease, severe hyper-
tension, peptic ulcer, and hypersensitivity to acetylsali-
cylic acid (ASA, aspirin) or pseudoephedrine (PSE).
Some medications were not allowed prior to the study
entry: for example, monoamine-oxidase inhibitors (30
days), antihistamines and antibiotics (7 days), analgesics
and antipyretics (24 hours), nasal decongestants
(12 hours), lozenges and throat sprays (6 hours), menthol
containing products (6 hours). Patients under anti-
coagulation therapy and pregnant or lactating females
were also excluded from the study.
The study was conducted in compliance with Good
Clinical Practice and approved by the South East Wales
Research Ethics Committee in Cardiff.
Study Design
According to the European Medicines Agency Guideline
“Guideline on Clinical Development of Fixed Combina-
tion Medicinal Products” fixed combination medicinal
products containing two or more active substances, it is
required to justify the particular combination of active
substances, and to provide evidence that the combination
has particular advantages in the clinical situation.14
Therefore this trial was designed to establish superiority
of the combination ASA 1,000mg and PSE 60mg
(Aspirin Complex) versus ASA 1,000mg and versus PSE
60mg alone in the indications of pain and nasal
congestion.
The study was designed as a randomized double-blind,
placebo-controlled, four-arm, parallel group study. Treat-
ments administered were two sachets (small disposable
bags) of 500mg ASA plus 30mg PSE granules or two
sachets of 500mg ASA granules or 2 sachets of 30mg
PSE granules or two sachets of placebo granules. Sachets
were taken orally after dissolving in a glass of water.
Double blinding was guaranteed since it was not possible
to distinguish between combination product, mono-
therapies, and placebo granules. All treatments were
dispensed as sachets containing white granules for
dissolving in water, and they had the same appearance,
taste, and no noticeable smell. Neither the investigators
nor the patients were aware of the nature of the treatments
and both were therefore blinded for any assessments. The
placebo contained all the flavoring and excipients that
were present in the other medications, which were
sucrose, hypromellose binder, orange flavor, and citric
acid.
Patients made two visits to the clinic. At visit 1,
screening and baseline assessments were completed.
Eligible patients received a single dose ofmedication, and
assessment of nasal airflow resistance, pain relief, pain
intensity, nasal congestion relief, and nasal congestion
intensity were made at 1, 2, 3, and 4 hours after dosing.
After the 4 hours assessments were completed, patients
left the center and they were asked to take 1–2more doses
on Day 1 and 3 doses per day for Days 2 and 3 with a
minimum dosing interval of 4 hours. At the evenings of
Days 1–3, patients were asked to assess pain intensity,
pain relief, nasal congestion intensity, and nasal conges-
tion relief. At the evening of Day 3, global assessment of
pain relief and global assessment of nasal congestion
relief was requested in addition to the other scores.
Patients were instructed to return to the center for visit 2
(follow-up visit) within 7 days of receiving the initial
dose, and after completing all required assessments they
ended participation in the study. Adverse event reporting
was done during the whole study period and also recorded
at the follow-up visit.
Assessments
The nasal airflow conductance was calculated from
measurements of nasal resistance to airflow. The
measurement of the combined inspiratory nasal resistance
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of both nasal passages was made with a rhinomanometer
(NR6, GM Instruments Ltd, Glasgow, UK) according to
the study site operating procedure for measurement of
nasal airflow resistance by posterior rhinomanometry.12
The technique of rhinomanometry requires the patient to
breathe into a face mask, and nasal airflow and pressure
are displayed on a computer screen. The computer
calculates a measure of nasal resistance as mean total
inspiratory nasal resistance (Pa/cm3 second). This tech-
nique of rhinomanometry is well established and has been
widely used over the years.6,12,15,16 Patients were asked to
gently blow their nose prior to any measurement. When
four breaths had been completed the computer automati-
cally stopped recording and patients removed the face
mask. After two recordings, the coefficient of variation
(CV) of the batch mean inspiratory nasal resistance (Pa/
cm3 second) was produced. If the CV was>10%, another
two measurements were taken. This was repeated until
two measurements with a CV10% were achieved. This
procedure helps to control errors in measurement such as
air leaks around the face mask.12
In addition to rhinomanometry, subjective intensity of
nasal congestion was measured, using a 4-point categori-
cal scale (0¼ no congestion, 1¼mild congestion, 2¼
moderate congestion, 3¼ severe congestion). Pain inten-
sity was determined as the combination of sore throat pain
and/or headache, also using a 4-point categorical scale
(0¼ no pain, 1¼mild pain, 2¼moderate pain, 3¼
severe pain). Subjective congestion relief and pain relief
were both measured by using a 5-point categorical scale
(0¼ no relief, 1¼ a little relief, 2¼ some relief, 3¼ a lot
of relief, 4¼ complete relief). Assessment of nasal
congestion relief and pain relief was measured using a
5-point categorical scale (0¼ poor, 1¼ fair, 2¼ good,
3¼ very good, 4¼ excellent). The assessments were
made every hour over 4 hours in the clinic and every
evening at home for days 1–3. Safety was assessed by
recording adverse events reported by patients in response
to non-leading questioning throughout the study, and by
the study physicians.
Statistical Analyses
The primary efficacy endpoints were the reduction of
nasal congestion, as measured by the area under the nasal
airflow conductance curve 0–4 hours post-first dose
(AUC0–4h) for the comparison ASA plus PSE versus
ASA, and the relief of pain as measured by the total pain
relief score 0–4 hours post-first dose (TOTPAR0–4h) for
the comparision ASA plus PSE versus PSE. Secondary
efficacy endpoints for nasal congestion were nasal
airflow conductance from baseline to 1, 2, and 3 hours,
(AUC0–1h, AUC0–2h, AUC0–3h), sum of subjective nasal
congestion intensity differences (SNCID) for the time-
period 0–4 hours (SNCID0–4h), and 0–3 days (SNCID0–
3D), total subjective nasal congestion relief (TNCR) for
the time period 0–4 hours (TNCR0–4h) and 0–3 days
(TNCR0–3D), and global assessment of nasal congestion
relief at the evening of day 3. Secondary endpoints pain
were sum of pain intensity differences (SPID) for the time
period 0–4 hours (SPID0–4h) and 0–3 days (SPID0–3D),
total pain relief (TOTPAR) for the time period 0-3 days
(TOTPAR0–3D), and global assessment of pain relief at
the evening of day 3.
In order to protect the overall type 1 error at the 0.05
level, the hierarchical testing procedure was conducted in
the following order: (1) reduction of nasal congestion and
(2) relief of pain.
In order to determine the sample size, the treatment
difference in TOTPAR0–4h was assumed to be 0.9
between ASA plus PSE versus PSE, with a standard
deviation of 3.0. The sample size needed to achieve 90%
of power for the total pain relief was 235 per group.
Assuming a treatment difference NAR AUC0–4h of 100
between ASA plus PSE versus ASA with a standard
deviation of 249, a sample size of 235 per group would
provide at least 99% of power for nasal airflow resistance.
This would result in an overall power of at least 90% for
both primary endpoints. Assuming the randomization
ratio of 2:2:2:1 and a dropout rate of 6%, approximately
250 patients were to be randomized into each of the ASA/
PSE combination, ASA alone, and PSE alone groups and
125 patients were to be randomized into the placebo
group.
Analysis of variance (ANOVA) was used to test for
treatment differences, and included treatment as a fixed
effect. Although other pair-wise comparisons were made
in order to present the complete efficacy profile, the
primary treatment comparison was made between: ASA
plus PSE and ASA for reduction of nasal congestion;
ASA plus PSE and PSE for relief of pain. Once a pair-
wise comparison was statistically non-significant, the
subsequent comparisons were to be technically ineligible
to be declared significant. However, all pair-wise com-
parisons were presented to provide a complete clinical
picture. Least squares (LS) means for each treatment and
the mean differences between treatments were calculated
and presented, along with the associated 95% confidence
intervals (CI) and P-values.
The primary efficacy endpoint (TOTPAR0–4h) and the
secondary efficacy endpoints (SNCID0–4h, SNCID0–3D,
TNCR0–4h, TNCR0–3D, SPID0–4h, SPID0–3D and TOT-
PAR0–3D) did not satisfy the assumptions of the proposed
ANOVA analysis and were analyzed using a non-
parametric Mann–Whitney U-test.
Trial Registration
The trial was registered on the EU Trials register June 5,
2009 and also had a EudraCT number 2009-011355-46.
The first patient was entered on trial September 15, 2009
and the last patient seen March 26, 2012.
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Results
Patients
There were 833 patients randomized to the study. All of
them were treated, and they comprised the safety
population. Four patients withdrew consent. The intent-
to-treat (ITT) population consisted of 829 patients. There
were no differences in the baseline demographics and
clinical features of the ITT population between treatment
groups. Stuffy and runny nose, as well as sore throat,
headache, and general discomfort were the major
symptoms of URTI at baseline.
Efficacy
Results of the statistical analysis of primary and
secondary endpoints for relief of nasal congestion and
relief of pain are presented in Tables 1 and 2, respectively.
1, 2, 3, and 4 hours after administration of a single dose of
the fixed combination of 1,000mg ASA plus 60mg PSE,
statistically significant superiority for nasal airflow
conductance was demonstrated compared to ASA
1,000mg (primary endpoint), and compared to placebo
(all P-values< .001), but not compared to PSE 60mg.
Subjective nasal congestion relief at 4 hours showed
statistically significant differences for the comparisons
ASA plus PSE versus ASA and versus placebo
(P< .001), but not for the comparison versus PSE.
Subjective nasal congestion intensity differences at
4 hours showed statistical difference of the combination
product versus placebo (P¼ .008), but not versus ASA
and versus PSE.
Table 2. P‐Values for Endpoint Pain Relief for ASA/PSE Comparisons
Outcome Comparison 0–4 hours Day 3
Total pain relief (TOTPAR)a ASA/PSE versus PSE 0.019b 0.348
ASA/PSE versus ASA 0.326 0.614
ASA/PSE versus Placebo <0.001 0.220
Sum of pain intensity differences (SPID)a ASA/PSE versus PSE 0.085 0.205
ASA/PSE versus ASA 0.748 0.876
ASA/PSE versus Placebo 0.421 0.946
Global pain relief ASA/PSE versus PSE n.a. 0.043
ASA/PSE versus ASA n.a. 0.828
ASA/PSE versus Placebo n.a. 0.078
n.a. not applicable.
aMann–Whitney U‐test.
bPrimary endpoint.
Table 1. P‐Values for Endpoint Nasal Congestion Relief for ASA/PSE‐Comparisons
Outcome Comparison 0–1 hours 0–2 hours 0–3 hours 0–4 hours Day 3
Airflow conductance area under
the curve (AUC)
ASA/PSE versus ASA <0.001 <0.001 <0.001 <0.001b n.a
ASA/PSE versus PSE 0.585 0.592 0.798 0.933 n.a.
ASA/PSE versus Placebo <0.001 <0.001 <0.001 <0.001 n.a.
Sum of subjective nasal congestion
intensity differences (SNCID)a
ASA/PSE versus ASA n.a n.a n.a. 0.144 0.969
ASA/PSE versus PSE n.a. n.a. n.a 0.647 0.371
ASA/PSE versus Placebo n.a. n.a. n.a. 0.008 0.048
Total subjective nasal congestion
relief (TCNR)a
ASA/PSE versus ASA n.a. n.a. n.a. <0.001 0.016
ASA/PSE versus PSE n.a n.a n.a 0.890 0.873
ASA/PSE versus Placebo n.a. n.a. n.a. <0.001 <0.001
Global nasal congestion relief ASA/PSE versus ASA n.a n.a n.a. n.a. 0.040
ASA/PSE versus PSE n.a. n.a. n.a. n.a. 0.207
ASA/PSE versus Placebo n.a. n.a. n.a. n.a. <0.001
n.a., not applicable.
aMann–Whitney U‐test.
bPrimary endpoint.
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Results of the changes in nasal airflow conductance over
4 hours, after a single dose of the four treatments are
presented in Figure 1. Figure 1 demonstrates that over the
first hour after treatment there was a mean increase in
nasal conductance in both the ASA plus PSE and PSE
alone treatment groups, whereas there was a decrease
airflow conductance in the ASA and the placebo
treatment groups. These changes in conductance were
maintained over the 4 hours study period. Figure 2
displays the changes in nasal congestion relief over
4 hours after treatment. Separation of treatments ASA
plus PSE and PSE versus treatments ASA and placebo are
clearly demonstrated. Nearly identical decongestion
relief curves for ASA plus PSE and PSE on the one
hand, and for ASA and placebo on the other hand, are
apparent. All of the treatment groups, including the
placebo group, exhibited nasal congestion relief.
After 3 days of multiple dose treatment, subjective
nasal congestion relief of the combination ASA plus PSE
was significantly different versus ASA (P¼ .016) and
versus placebo (P< .001), but not versus PSE. After
3 days of treatment subjective nasal congestion intensity
differences were significant for the combination ASA
plus PSE versus placebo (P¼ .048), but not versus ASA
and versus PSE. The global assessment of nasal
congestion relief determined at the end of the 3-day
treatment period showed statistically significant differ-
ences of the combination product compared to ASA
(P¼ .04) and compared to placebo (P< .001), but not
compared to PSE.
Total pain relief, TOTPAR0–4h, of the combination
product ASA plus PSE was statistically significant
different 0–4 hours after administration of a single
dose, compared to PSE (P¼ .019, primary endpoint)
and compared to placebo (P< .001), but not compared to
ASA. Comparison of the combination of ASA plus PSE
with PSE, ASA and placebo with respect to sum of pain
intensity differences (SPID0–4h) did not reveal any
statistically significant differences. Multiple dosing after
3-days treatment did not reveal any differences for total
pain relief and for sum of pain intensity differences for
any comparison. The global assessment of pain relief
determined at the end of the 3 days treatment period
showed significant differences of the combination
product compared to PSE (P¼ .043), but not compared
to ASA and placebo. Figure 3 presents the 4 hours time
curve of ASA plus PSE, ASA, PSE, and placebo for pain
relief.
Safety
In this study no unexpected adverse events (AE) occurred.
Overall one serious adverse event (SAE) occurred. The
patient was treated with aspirin plus PSE. The SAE was a
fall, and feeling faint after the fall. The subject was
hospitalized and discharged the same day. No medication
was given. The event fully resolved without any sequelae.
The investigator considered that the fall and the faint
feeling were not related to the study drug. AE were
reported by 37 (15.7%) patients receiving ASA 1,000mg
plus PSE 60mg, by 27 (11.3%) patients receiving ASA
1,000mg, 28 (11.8%) patients receiving PSE 60mg, and
14 (11.6%) patients receiving placebo. No patient was
withdrawn from the study due to an AE. The most
frequent AE were from the gastrointestinal system (ASA
Figure 1. Mean ( SEM) nasal airflow conductance (cm3 second) before and up to 4 hours after dosing.
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plus PSE: 7.7%, ASA: 7.5%, PSE: 5.1%, placebo: 4.1%)
followed by nervous system disorders (ASA plus PSE:
4.3%, ASA: 0.8%, PSE: 1.7%, placebo: 5.0%). Treat-
ment-related AE were generally less frequent. In total
6.4%, 5.4%, 3.4%, and 3.3% of AE occurred after
treatment with ASA plus PSE, ASA, PSE, and placebo,
respectively. The gastrointestinal system was involved in
4.7% of AE for ASA plus PSE, 3.8% of AE for ASA,
2.1% of AE for PSE, and 1.7% of AE for placebo.
Discussion
The results of this study demonstrate that a combination
of ASA plus PSE can provide simultaneous relief of the
Figure 2. Mean ( SEM) nasal congestion relief score before and up to 4 hours after dosing.
Figure 3. Mean ( SEM) pain relief score before and up to 4 hours after dosing.
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symptom of nasal congestion and pain related symptoms
of common cold such as headache and sore throat. The
objective relief of the symptom of nasal congestion by the
combination medicine is clearly apparent in Figure 1 that
illustrates the objective changes in nasal conductance to
airflow. The subjective relief of nasal congestion of the
combination medicine is clearly shown in Figure 2. The
relief of the pain related symptoms by the combination
medicine is shown in Figure 3. It is interesting that the
objective reductions in nasal conductance (increased
congestion) seen with treatment with ASA alone and
placebo in Figure 1, do not correlate with the subjective
improvements in congestion relief (decreased conges-
tion) for treatments with ASA alone and placebo seen in
Figure 2. This lack of correlation between objective and
subjective measures of congestion, exactly mirrors the
findings of a study on a paracetamol and pseudoephedrine
combination,15 and it may be explained by the subjective
scores of congestion relief being more susceptible to a
placebo effect than the objective measures of nasal
conductance.
Nasal congestion and pain are among the most
common and most severe symptoms of common cold.10
Single and multiple dose administration of the combina-
tion of ASA plus PSE provide a higher decongestant
effect than placebo and the single active ASA, but not
than the single active PSE. Otherwise the combination of
ASA plus PSE provides a higher pain relieving effect than
placebo and single active PSE, but also than the single
active ASA.
In this study 4-point and 5-point categorical scales
have been used. The 4-point scale was used to assess the
intensity of nasal congestion and of pain at given time
points, whereas assessment of congestion relief and of
pain relief at given time points was utilized by using the 5-
point scale. In this study, the results demonstrate
statistically significant differences for pain and conges-
tion relief at 4 hours for the comparisons ASA plus PSE
versus PSE and versus ASA, respectively, but not for the
corresponding measurements of pain and congestions
intensity differences. It is possible that the 4-point scales
are less discriminative than 5-point scales, and this would
explain the non-significant differences observed between
the fixed combination product and the single active
ingredient ASA with respect to the measurement of nasal
congestion intensity differences and the single active
ingredient PSE with respect to the measurement of pain
intensity differences. The same comparisons showed
statistically significant differences when applying the
measurements of pain and congestion relief using 5-point
scales.
The observation that day-3 assessment for differ-
ences in nasal congestion relief for the comparison
ASA plus PSE versus ASA was statistically signifi-
cant, whereas day-3 assessment for differences in pain
relief for the comparison ASA plus PSE versus PSE
was not statistically significant, may be related to the
rapid recovery of some patients from the common cold
syndrome of symptoms, causing an increased variabil-
ity of the mean data towards the end of the study
period.
Conclusions
This study demonstrates that a combination therapy of
ASA plus PSE provides safe and effective relief of both
common cold pain related symptoms and nasal conges-
tion. The fixed combination of ASA plus PSE is superior
to the single active ingredients ASA alone and PSE alone
and this study provides justification to use the fixed
combination ASA plus PSE in the treatment of URTI with
acute pain and nasal congestion.
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